Trials / Recruiting
RecruitingNCT04187443
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
Conditions
- Diabetic Macular Edema
- Macular Edema
- Type 2 Diabetes With Diabetic Macular Edema
- Type 1 Diabetes With Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MS-553 | MS-553 |
Timeline
- Start date
- 2020-06-02
- Primary completion
- 2026-10-30
- Completion
- 2026-12-30
- First posted
- 2019-12-05
- Last updated
- 2025-09-29
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04187443. Inclusion in this directory is not an endorsement.